News for NRx Pharmaceuticals, Inc. (NRXP)

PR NewswireMIAMI, June 26, 2025 Cohen and Associates is a highly respected neuropsychiatry clinic in western FloridaCohen to serve as foundational clinic i

NRx Pharmaceuticals (NRXP) and its subsidiary, HOPE Therapeutics, are poised to enhance their clinical care capabilities by signing a binding Letter of Intent t

NRx Pharmaceuticals (NRXP) has filed an application under the FDA's recently introduced National Priority Voucher (NPV) program for its innovative formulation,

On June 23, 2025, NRX Pharmaceuticals (NRXP) received a reaffirmation of its 'Buy' rating from Jason Kolbert of D. Boral Capital. The analyst has decided to mai

NRx Pharmaceuticals (NRXP) files for the new FDA Commissioner's National Priority Voucher (CNPV) for NRX-100, aiming to expedite review times. The CNPV

Summary: NRx Pharmaceuticals (NRXP) plans a $150 million securities sale, boosting shares by 2.2% in after-hours trading. Wall Street analysts set a bull

NRx Pharmaceuticals (NRXP) has filed a registration to raise up to $150 million through a mixed securities offering. This move aims to provide the company with

NRX Pharmaceuticals (NRXP) continues to capture the attention of analysts and investors alike. The latest insights from D. Boral Capital, provided by analyst Ja

PR NewswireWILMINGTON, Del., June 16, 2025 WILMINGTON, Del., June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals",

NRx Pharmaceuticals (NRXP) forms a strategic investor relations partnership with astr partners, targeting investor engagement. The collaboration occurs

NRX Pharmaceuticals (NRXP) has received a continued 'Buy' rating from analyst Jason Kolbert at D. Boral Capital. The recommendation was announced on June 6, 202

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (NRXP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Loss from Operations: Reduced by approximately $9.3 million, or 33.5%, to $18.5 million for the year ended December 31, 2024.Research and Development Expense:

Mar 17, 2025 / 12:30PM GMTOperator Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and full year 2024 earnings call. At this time,

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ETCompany ParticipantsMatthew Duffy - Chief Business...

PR NewswireWILMINGTON, Del., March 17, 2025 Initiated filing of a New Drug Application ("NDA") to the FDA for NRX-100 (IV Ketamine) for the treatment of Su

Discover NRx Pharmaceuticals' FY financials, with a GAAP EPS of -$2.36 and $8.5M in recent financings to sustain operations through 2025.

PR NewswireWILMINGTON, Del., March 12, 2025 - Conference call to take place at 8:30am ET -WILMINGTON, Del., March 12, 2025 /PRNewswire/ -- NRx Pharmaceutic